Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

FDA Designates Vast’s BIOC11 a Qualified Infectious Disease Product

The U.S. Food and Drug Administration (FDA) has designated Vast Therapeutics’ BIOC11 a Qualified Infectious Disease Product (QIDP) for the treatment of people with cystic fibrosis (CF) who have chronic pulmonary infections due to Pseudomonas aeruginosa. The QIDP designation makes BIOC11 eligible for priority-review and fast-track statuses…

Experts Highlight Obstacles in Delivering New CF Therapies

Care for cystic fibrosis (CF) has improved substantially in recent decades, but there are still challenges ahead, particularly in ensuring that all patients have access to the best available care, according to a new study. The Lancet, a renowned medical journal, commissioned nearly 40 experts to write a paper…